Literature DB >> 27283751

Combining Stimulus-Triggered Release and Active Targeting Strategies Improves Cytotoxicity of Cytochrome c Nanoparticles in Tumor Cells.

Moraima Morales-Cruz1, Alejandra Cruz-Montañez2, Cindy M Figueroa2, Tania González-Robles2, Josue Davila3, Mikhail Inyushin4, Sergio A Loza-Rosas2, Anna M Molina2, Laura Muñoz-Perez2, Lilia Y Kucheryavykh3, Arthur D Tinoco2, Kai Griebenow2.   

Abstract

Proteins often possess highly specific biological activities that make them potential therapeutics, but their physical and chemical instabilities during formulation, storage, and delivery have limited their medical use. Therefore, engineering of nanosized vehicles to stabilize protein therapeutics and to allow for targeted treatment of complex diseases, such as cancer, is of considerable interest. A micelle-like nanoparticle (NP) was designed for both, tumor targeting and stimulus-triggered release of the apoptotic protein cytochrome c (Cyt c). This system is composed of a Cyt c NP stabilized by a folate-receptor targeting amphiphilic copolymer (FA-PEG-PLGA) attached to Cyt c through a redox-sensitive bond. FA-PEG-PLGA-S-S-Cyt c NPs exhibited excellent stability under extracellular physiological conditions, whereas once in the intracellular reducing environment, Cyt c was released from the conjugate. Under the same conditions, the folate-decorated NP reduced folate receptor positive HeLa cell viability to 20%, while the same complex without FA only reduced it to 80%. Confocal microscopy showed that the FA-PEG-PLGA-S-S-Cyt c NPs were internalized by HeLa cells and were capable of endosomal escape. The specificity of the folate receptor-mediated internalization was confirmed by the lack of uptake by two folate receptor deficient cell lines: A549 and NIH-3T3. Finally, the potential as antitumor therapy of our folate-decorated Cyt c-based NPs was confirmed with an in vivo brain tumor model. In conclusion, we were able to create a stable, selective, and smart nanosized Cyt c delivery system.

Entities:  

Keywords:  active targeting; biodegradable polymer; drug delivery; nanoparticle; protein drug; triggered release

Mesh:

Substances:

Year:  2016        PMID: 27283751      PMCID: PMC4969193          DOI: 10.1021/acs.molpharmaceut.6b00461

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  33 in total

1.  Cytochrome C encapsulating theranostic nanoparticles: a novel bifunctional system for targeted delivery of therapeutic membrane-impermeable proteins to tumors and imaging of cancer therapy.

Authors:  Santimukul Santra; Charalambos Kaittanis; J Manuel Perez
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

Review 2.  Treating metastatic cancer with nanotechnology.

Authors:  Avi Schroeder; Daniel A Heller; Monte M Winslow; James E Dahlman; George W Pratt; Robert Langer; Tyler Jacks; Daniel G Anderson
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

3.  Receptor-targeted gene delivery via folate-conjugated polyethylenimine.

Authors:  W Guo; R L Lee
Journal:  AAPS PharmSci       Date:  1999

Review 4.  To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.

Authors:  Fabienne Danhier; Olivier Feron; Véronique Préat
Journal:  J Control Release       Date:  2010-08-24       Impact factor: 9.776

5.  Tumor cell targeting using folate-conjugated fluorescent quantum dots and receptor-mediated endocytosis.

Authors:  Er-Qun Song; Zhi-Ling Zhang; Qing-Ying Luo; Wen Lu; Yun-Bo Shi; Dai-Wen Pang
Journal:  Clin Chem       Date:  2009-03-12       Impact factor: 8.327

6.  Doxorubicin loaded pH-sensitive micelle: antitumoral efficacy against ovarian A2780/DOXR tumor.

Authors:  Dongin Kim; Eun Seong Lee; Kyeongsoon Park; Ick Chan Kwon; You Han Bae
Journal:  Pharm Res       Date:  2008-05-01       Impact factor: 4.200

Review 7.  Therapeutic nanoparticles for drug delivery in cancer.

Authors:  Kwangjae Cho; Xu Wang; Shuming Nie; Zhuo Georgia Chen; Dong M Shin
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

Review 8.  Nanocarriers for the targeted treatment of ovarian cancers.

Authors:  Julie Tomasina; Stéphanie Lheureux; Pascal Gauduchon; Sylvain Rault; Aurélie Malzert-Fréon
Journal:  Biomaterials       Date:  2012-11-20       Impact factor: 12.479

9.  Microglia Activate Migration of Glioma Cells through a Pyk2 Intracellular Pathway.

Authors:  Kimberleve Rolón-Reyes; Yuriy V Kucheryavykh; Luis A Cubano; Mikhail Inyushin; Serguei N Skatchkov; Misty J Eaton; Jeffrey K Harrison; Lilia Y Kucheryavykh
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

10.  Two-step nanoprecipitation for the production of protein-loaded PLGA nanospheres.

Authors:  Moraima Morales-Cruz; Giselle M Flores-Fernández; Myreisa Morales-Cruz; Elsie A Orellano; José A Rodriguez-Martinez; Mercedes Ruiz; Kai Griebenow
Journal:  Results Pharma Sci       Date:  2012
View more
  8 in total

Review 1.  Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain.

Authors:  Mayur M Patel; Bhoomika M Patel
Journal:  CNS Drugs       Date:  2017-02       Impact factor: 5.749

Review 2.  Nanomaterial-based blood-brain-barrier (BBB) crossing strategies.

Authors:  Jinbing Xie; Zheyu Shen; Yasutaka Anraku; Kazunori Kataoka; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2019-09-14       Impact factor: 12.479

3.  Photoresponsive Block Copolymer Prodrug Nanoparticles as Delivery Vehicle for Single and Dual Anticancer Drugs.

Authors:  Gargi Biswas; Bikash Chandra Jena; Saikat Maiti; Pousali Samanta; Mahitosh Mandal; Dibakar Dhara
Journal:  ACS Omega       Date:  2017-10-12

4.  Targeted Delivery of Nanoparticulate Cytochrome C into Glioma Cells Through the Proton-Coupled Folate Transporter.

Authors:  Yuriy V Kucheryavykh; Josue Davila; Jescelica Ortiz-Rivera; Mikhael Inyushin; Luis Almodovar; Miguel Mayol; Moraima Morales-Cruz; Alejandra Cruz-Montañez; Vanessa Barcelo-Bovea; Kai Griebenow; Lilia Y Kucheryavykh
Journal:  Biomolecules       Date:  2019-04-18

Review 5.  Smart Targeting To Improve Cancer Therapeutics.

Authors:  Moraima Morales-Cruz; Yamixa Delgado; Kai Griebenow; Betzaida Castillo; Cindy M Figueroa; Anna M Molina; Anamaris Torres; Melissa Milián
Journal:  Drug Des Devel Ther       Date:  2019-10-30       Impact factor: 4.162

6.  Cytochrome c: Using Biological Insight toward Engineering an Optimized Anticancer Biodrug.

Authors:  Louis J Delinois; Omar De León-Vélez; Adriana Vázquez-Medina; Alondra Vélez-Cabrera; Amanda Marrero-Sánchez; Christopher Nieves-Escobar; Daniela Alfonso-Cano; Delvin Caraballo-Rodríguez; Jael Rodriguez-Ortiz; Jemily Acosta-Mercado; Josué A Benjamín-Rivera; Kiara González-González; Kysha Fernández-Adorno; Lisby Santiago-Pagán; Rafael Delgado-Vergara; Xaiomy Torres-Ávila; Andrea Maser-Figueroa; Gladimarys Grajales-Avilés; Glorimar I Miranda Méndez; Javier Santiago-Pagán; Miguel Nieves-Santiago; Vanessa Álvarez-Carrillo; Kai Griebenow; Arthur D Tinoco
Journal:  Inorganics (Basel)       Date:  2021-11-16

7.  Optimization and Characterization of Protein Nanoparticles for the Targeted and Smart Delivery of Cytochrome c to Non-Small Cell Lung Carcinoma.

Authors:  Vanessa Barcelo-Bovea; Irivette Dominguez-Martinez; Freisa Joaquin-Ovalle; Luis A Amador; Elizabeth Castro-Rivera; Kristofer Medina-Álvarez; Anthony McGoron; Kai Griebenow; Yancy Ferrer-Acosta
Journal:  Cancers (Basel)       Date:  2020-05-13       Impact factor: 6.639

8.  Folate-Decorated Cross-Linked Cytochrome c Nanoparticles for Active Targeting of Non-Small Cell Lung Carcinoma (NSCLC).

Authors:  Irivette Dominguez-Martinez; Freisa Joaquin-Ovalle; Yancy Ferrer-Acosta; Kai H Griebenow
Journal:  Pharmaceutics       Date:  2022-02-24       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.